Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …

Lymphoma (malignant lymphoma or lymphosarcoma) comprises a diverse group of
neoplasms that have in common their origin from lymphocytes. The neoplasms usually arise …

Background Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug
chemotherapy regimen represents the treatment cornerstone; however, cure is rarely …

Background Doxorubicin (DOX) is widely used in both human and veterinary oncology
although the onset of multidrug resistance (MDR) in neoplastic cells often leads to …

Treatment of neoplastic diseases in companion animals is one of the most important
problems of modern veterinary medicine. Given the growing interest in substances of natural …

Pet dogs develop spontaneous diffuse large B cell lymphoma (DLBCL), and veterinary
clinical trials have been employed to treat canine DLBCL and to inform clinical trials for their …

Osteosarcoma (OSA) is the most frequently diagnosed primary malignant bone tumor in
humans and dogs. In both species, standard chemotherapy can be limited by multidrug …

Osteosarcoma (OSA) is the most common malignant bone neoplasia in humans and dogs.
In dogs, treatment consists of surgery in combination with chemotherapy (mostly carboplatin …

Acquired chemoresistance during chemotherapy, often accompanied by cross-and multi-
resistance, limits therapeutic outcomes and leads to recurrence. In order to create in vitro …

The emergence of multidrug resistance (MDR) is one of the main factors that impair
therapeutic outcome in cancer therapy. Among all the factors that contribute to MDR …